AGT is developing screening tests are microRNA-based blood tests. AGT has identified certain key circulating microRNAs as biomarkers for AD staging, differentiating individuals currently suffering AD into three different stages: mild, moderate and severe, distinguished from MCI victims and the ADAR group. Separation of these stages by cognitive tests such as mini-mental status
evaluation (MMSE) has been quantitatively validated by increased levels of key microRNAs in the plasma. AGT has proven methods to stabilize these microRNA species in plasma at room temperature for 72 hours, sufficient time for sample shipment from Point-of-Care facilities to AGT for analysis. Through a contract with Jewish General Hospital (JGH), in Montréal, Québec, AGT has collected blood samples from close to 200 AD patients and 200 normal elderly controls, forming a strong biorepository for the AD diagnostic. AGT is generating similar biorepositories for the MCI and ADAR groups with the JGH Memory Clinic and the JGH Alzheimer Risk Assessment Clinic, through a separate contract.